Last reviewed · How we verify
Lipaglyn (SAROGLITAZAR)
Lipaglyn (generic name: SAROGLITAZAR) is a Small molecule drug developed by Cadila Healthcare. It is currently FDA-approved for Diabetic dyslipidemia associated with type 2 diabetes mellitus.
Lipaglyn is a small molecule that acts as an agonist to the peroxisome proliferator-activated receptor alpha. It is classified as a peroxisome proliferator-activated receptor alpha agonist.
At a glance
| Generic name | SAROGLITAZAR |
|---|---|
| Sponsor | Cadila Healthcare |
| Target | Peroxisome proliferator-activated receptor alpha |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetic dyslipidemia associated with type 2 diabetes mellitus
Common side effects
Key clinical trials
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy (PHASE3)
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (PHASE3)
- Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease (PHASE1)
- Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (PHASE3)
- Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII) (PHASE2)
- Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis (PHASE2)
- Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease (PHASE1)
- Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipaglyn CI brief — competitive landscape report
- Lipaglyn updates RSS · CI watch RSS
- Cadila Healthcare portfolio CI
Frequently asked questions about Lipaglyn
What is Lipaglyn?
What is Lipaglyn used for?
Who makes Lipaglyn?
What is the generic name of Lipaglyn?
What development phase is Lipaglyn in?
What does Lipaglyn target?
Related
- Target: All drugs targeting Peroxisome proliferator-activated receptor alpha
- Manufacturer: Cadila Healthcare — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Diabetic dyslipidemia associated with type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing